Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study

Shijia Zhang,Kimberly Tang,Guihong Wan,Nga Nguyen,Chenyue Lu,Pearl Ugwu-Dike, Neel Raval,Jayhyun Seo, Nora A. Alexander,Ruple Jairath,Jordan Phillipps,Bonnie W. Leung, Kathleen Roster,Wenxin Chen,Leyre Zubiri,Genevieve Boland,Steven T. Chen,Hensin Tsao,Shadmehr Demehri,Nicole R. LeBoeuf

Journal of the American Academy of Dermatology（2023）

引用 0|浏览3

暂无评分

摘要

Patients on immune checkpoint inhibitors (ICIs) who developed cutaneous immune-related adverse events (cirAEs) had favorable outcomes. This was especially notable for melanoma patients who had cirAEs, both those with vitiligo and other morphologies.Development of cirAEs in ICI-treated patients can be used to prognosticate survival and guide treatment decisions.

查看译文

关键词

cutaneous adverse reactions,immune checkpoint inhibitor,immune-related adverse events,immunotherapy,melanoma,mortality,oncology,skin toxicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要